The aim of this study was to investigate the prognostic impact of baseline tumor burden and loci on the efficacy of first line renal cancer treatment with sunitinib. Baseline and on-treatment CT scans were evaluated. Both the Kaplan-Meier and Weibull modelling survival estimators have been used to describe sunitinib treatment response. Logistic regression was used to confirm associations between tumor site, burden and survival. Additionally, analysis of the metastases co-occurrence was conducted using the Bayesian inference on treated and external validation cohorts. 100 patients with metastatic clear cell renal cell carcinoma were treated with sunitinib in this study. Presence of metastases in the abdominal region (HR = 3.93), and the number of brain metastases correlate with shorter PFS, while the presence of thoracic metastases (HR = 0.47) with longer PFS. Localization of metastases in the abdominal region significantly impacts risk of metastases development in other locations including bone and brain metastases. Biology of metastases, in particular their localization, requires further molecular and clinical investigation.
Scientific reports. 2019 May 23*** epublish ***
Anna M Czarnecka, Anna Brodziak, Pawel Sobczuk, Cezary Dendek, Dominika Labochka, Jan Korniluk, Ewa Bartnik, Cezary Szczylik
Department of Oncology, Military Institute of Medicine, Warsaw, Poland. ., Department of Oncology, Military Institute of Medicine, Warsaw, Poland., Faculty of Mathematics and Information Science, Warsaw University of Technology, Warsaw, Poland., Institute of Genetics and Biotechnology, Faculty of Biology, University of Warsaw, Warsaw, Poland.